Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
355.5 EUR | +2.16% | +1.86% | -1.11% |
May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play | |
Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.11% | 3.12B | B- | ||
-9.19% | 6.64B | B- | ||
+24.75% | 3.7B | B- | ||
+6.08% | 1.45B | - | ||
-15.13% | 1.37B | B | ||
-25.63% | 1.24B | C- | ||
-7.62% | 1.21B | - | ||
-10.84% | 1.17B | - | ||
-.--% | 1.05B | - | ||
-7.07% | 820M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIRP Stock
- Ratings Virbac